Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?

Ahmed BS, Ryan Phelps B, Reuben EB, Ferris RE

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
24300443

DOI
10.1093/trstmh/trt108

Indexing Status
Subject indexing assigned by NLM

MeSH
Anti-Retroviral Agents /economics /therapeutic use; Child, Preschool; Cohort Studies; Coinfection; Cost-Benefit Analysis; Drug Therapy, Combination; Female; HIV Infections /complications /drug therapy; HIV Protease Inhibitors /economics /therapeutic use; Humans; Incidence; Infant; Lopinavir /economics /therapeutic use; Malaria /economics /epidemiology /prevention & control; Male; Quality-Adjusted Life Years; Ritonavir /economics /therapeutic use; Uganda /epidemiology

AccessionNumber
22014005865

Date bibliographic record published
18/02/2014